Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1Phase 1 1

Status

Recruiting 54Unknown 17Completed 15Not yet recruiting 9Terminated 7Active not recruiting 5Suspended 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 14Thoracic 5Other solid neoplasm 5Myeloid 5Lymphoid 4Breast 4Dermatologic 3Sarcoma 2Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1Plasma cell 1Head & Neck 1CNS 1

Conditions

Advanced Solid Tumor 3Advanced Solid Tumors 1Advanced KRAS G12D Mutant Solid Tumors 1

Interventions

pembrolizumab 27Pemetrexed 10Nivolumab 10Cyclophosphamide 10Carboplatin 10atezolizumab 8Specimen Handling 8Cisplatin 8Ipilimumab 6Biopsy 6fludarabine 5Injections 5tislelizumab 4spartalizumab 4Vincristine 4Radiotherapy 4Proton Therapy 4Platinum 4Paclitaxel 4Drug Therapy 4Docetaxel 4Bevacizumab 41,2-diaminocyclohexaneplatinum II citrate 4sintilimab 3durvalumab 3Trastuzumab 3Etoposide 3Cetuximab 3zimberelimab 2trametinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Injections × Other solid neoplasm × Clear all
NCT05438329 2026-05-12

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1/2 Active not recruiting
1,123 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05906537 2026-05-12

SKB410 for Injection in Solid Tumors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 1 Active not recruiting
54 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT06927687 2026-04-29

Study of ZG005 in Patients With Advanced Solid Tumors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Active not recruiting
50 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT06057922 2026-03-12

A Study YL201 in Patients With Selected Advanced Solid Tumors

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2 Active not recruiting
990 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT06385678 2025-09-19

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Active not recruiting
47 enrolled
Other solid neoplasm

Advanced KRAS G12D Mutant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡